Sixth Street-backed Caris Life Sciences targets $5.3 billion valuation in US IPO
Cancer diagnostic firm Caris Life Sciences said on Monday it is targeting a valuation of up to $5.3 billion in its U.S. initial public offering, as the market for new
June 09, 2025